- איגודים
- אונקולוגיה
- אורולוגיה
- טיפול נמרץ
- מומחים צעירים
- מיילדות וגינקולוגיה
- משפחה
- נוירולוגיה
- עור ומין
- המטולוגיה
- חברות
- אורואונקולוגיה
- אם ועובר
- אנדוסקופיה גינקולוגית
- גידולי מערכת העיכול
- גיל המעבר
- החברה להפרעת קשב
- החברה לכאב ראש
- הפרעות תנועה
- טיפול בכאב
- טיפול פליאטיבי
- מחלות מטבוליות
- מלנומה
- סרטן השד
- סרטן ריאות
- רדיותרפיה
- רפואת אורחות חיים
מן הרשת
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non–small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer
An exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab
CTCs Serve as Prognostic Marker for Outcomes in Metastatic Hormone-Sensitive Prostate Cancer
Circulating tumor cell (CTC) count is a beneficial biomarker in patients with metastatic castration-sensitive prostate cancer (mCSPC), according to Amir Goldkorn, MD, who added that the use of CTCs could be of critical importance in future research
Radiation Therapy, Brachytherapy Outcomes Similar for Localized Prostate Cancer
Long-term survival among men with intermediate-risk prostate cancer did not differ regardless of whether they received stereotactic body radiation therapy (SBRT), dose-escalated external beam radiation (DE-EBRT) or brachytherapy (BT), according to a database analysis
Urine-Based Liquid Biopsy Test Outperforms Urine Cytology in Detecting Bladder Cancer
Analysis of DNA copy number variants in the cells exfoliated in urine shows better sensitivity and similar specificity in detecting urothelial carcinoma compared with urine cytology, according to a study published in Clinical Cancer Research
Treatment Based on Advanced Molecular Imaging Can Improve DFS in Prostate Cancer
The use of advanced molecular imaging with the PET radiotracer fluciclovine (18F) to inform treatment decisions can lead to improved disease-free survival (DFS) rates in patients with recurrent prostate cancer, according to data from the phase 2/3 EMPIRE-1 (NCT01666808) trial presented during the 2020 American Society for Radiation Oncology Annual Meeting
מחקרים וחדשות רפואה
-
מן הרשת03.06.2021, 16:52
-
טיפול בקרינה03.06.2021, 14:49
-
לוקמיה לימפובלסטית03.06.2021, 14:19
-
תיאור מקרה03.06.2021, 14:08
7 הכי נקראות
-
1
-
2
-
3
-
4
-
5
-
6
-
7
תגובות אחרונות